Rational repurposing, synthesis,
<i>in vitro</i>
and
<i>in silico</i>
studies of chromone-peptidyl hybrids as potential agents against
<i>Leishmania donovani</i>
作者:Ahmed H. E. Hassan、Waleed A. Bayoumi、Selwan M. El-Sayed、Trong-Nhat Phan、Yeon Ju Kim、Chae Hyeon Lee、Soo Bin Cho、Taegeun Oh、Gyeongpyo Ham、Kazem Mahmoud、Joo Hwan No、Yong Sup Lee
DOI:10.1080/14756366.2023.2229071
日期:2023.12.31
Abstract A chromone-peptidyl hybrids series was synthesised and rationally repurposed towards identification of potential antileishmanial hits against visceral leishmaniasis. Three hybrids 7c, 7n, and 7h showed potential IC50 values (9.8, 10, and 12 µM, respectively) which were comparable to erufosine IC50 (9.8 µM) but lower potency than miltefosine IC50 (3.5 µM). Preliminary assessment of cytotoxicity
摘要 合成了色酮-肽基杂合体系列,并合理地重新调整用途,以鉴定针对内脏利什曼病的潜在抗利什曼病。三种杂交体7c、7n和7h显示出潜在的 IC 50值(分别为 9.8、10 和 12 µM),与埃卢福辛 IC 50 (9.8 µM)相当,但效力低于米替福辛 IC 50 (3.5 µM)。使用人 THP-1 细胞对细胞毒性进行初步评估,发现色酮-肽杂合体7c和7n在高达 100 µM 时无细胞毒性,而埃吕福辛和米替福辛的 CC 50分别为 19.4 µM 和 >40 µM。计算机模拟研究指出,肽基部分的N - p-甲氧基苯乙基取代基以及色酮部分苯环的氧基取代功能是与Ld CALP 结合的关键因素。总之,这些发现表明色酮-肽基杂合体7c和7n作为潜在的和预期的非细胞毒性抗利什曼病命中化合物,可用于开发潜在的抗内脏利什曼病抗利什曼病药物。